laitimes

Minfa Aluminum's stock price changed, and the rise in the price of aluminum ingots had little impact on performance; Red Star developed battery-grade lithium carbonate and other products with low gross profit margins

author:Finance

Financial circle network September 9 news This evening's important announcement to take a look at - Red Star Development: the company's battery-grade lithium carbonate and other products have a low gross profit margin, Anhui Construction Engineering: subsidiaries won the bid for two construction projects with a total amount of 1.711 billion, Minfa Aluminum: The recent rise in aluminum ingot prices has little impact on the company's performance...

USI: August consolidated operating income increased by 12.08% year-on-year

USI Electronics (601231) announced on the evening of September 9 that the company's consolidated operating income in August was 4.672 billion yuan, an increase of 12.08% year-on-year, and an increase of 14.97% over the consolidated operating income in July. The company's consolidated operating income from January to August was 31.009 billion yuan, an increase of 27.17% year-on-year.

Shanghai Construction Engineering: The subsidiary intends to participate in the establishment of an equity investment fund of 480 million yuan

Shanghai Construction Engineering (600170) announced on the evening of September 9 that The Company's wholly-owned subsidiary, Construction Engineering Investment, signed an agreement with Shenchuang Industrial City Management Center to jointly invest in the establishment of Shanghai Shenchuang Industrial City Private Equity Fund Partnership (Limited Partnership) ("Shenchuang Industrial City Fund"). Among them, Construction Engineering Investment, as a limited partner, invested 480 million yuan, accounting for 12.42% of the total subscribed capital of the fund. At the same time, Construction Engineering Investment will invest RMB2.4 million in the Shenchuang Industrial City Management Center (the general partner GP of the Shenchuang Industrial City Fund) as a limited partner LP, accounting for 10% of the total subscription of the partnership.

Dawson Shares: Subsidiary Land Acquisition and Storage Estimated pre-tax gain of 12.24 million yuan

Dawson Co., Ltd. (603800) announced on the evening of September 9 that the Management Committee of Nantong SuXitong Science and Technology Industrial Park intends to recover the industrial land use rights and aboveground attachments and other assets of its wholly-owned subsidiary, Nantongsen, located at No. 8 Haidi Road, Chongchuan District, Nantong City, and pay compensation of 84.0907 million yuan. The transaction is expected to generate a total pre-tax gain of $12.24 million for the Company. Due to market reasons, the South Passage Forest has not started enough and has been in a state of suspension since 2019, and this transaction is conducive to the revitalization of the company's existing assets.

Chengyi Pharmaceutical: The controlling shareholder intends to transfer and reduce its shareholding by no more than 5.82%.

Chengyi Pharmaceutical (603811) announced on the evening of September 9 that Yan Yiyi, the company's controlling shareholder and actual controller, intends to reduce its holding of no more than 13.6 million shares of the company's shares through agreement transfer within 6 months after 3 trading days, that is, no more than 5.82% of the company's total share capital.

Zhengfan Technology: Shareholders intend to reduce their total holdings of the company by not more than 11.08%.

Zhengfan Technology (688596) announced on the evening of September 9 that the private equity fund, Hengqi and its co-actors, Songyang and Jiuzhou, intend to reduce their holdings of no more than 13.0333 million shares of the company, that is, not more than 5.08% of the total number of shares in the company; Jiayin Youcai and its consistent actor Youcai Zhongci intend to reduce their holdings of no more than 15.39 million shares of the company, that is, not more than 6% of the total number of shares of the company.

China Grain Stream disclosed the results of the increase: Gao Yi assets were allocated about 100 million yuan

On the evening of September 9, China Grain Logistics (603565) disclosed the report on the issuance of non-public shares, determining that the issue price was 29.84 yuan per share, the number of shares issued was 92.0911 million shares, and the total amount of funds raised was about 2.748 billion yuan. The target of the offering was finally determined to be 20, of which Gao Yi's assets were allocated about 100 million yuan.

Shenzhen Airport: Passenger throughput in August fell by 44.66% year-on-year

Shenzhen Airport (000089) disclosed its monthly operating report on the evening of September 9, and the passenger throughput in August was 2.2132 million passengers, down 44.66% year-on-year; the cargo and mail throughput was 124,800 tons, an increase of 4.57% year-on-year. From January to August, the passenger throughput was 23.7309 million passengers, an increase of 8.03% year-on-year, and the cargo and mail throughput was 1.0143 million tons, an increase of 18.4% year-on-year.

Sunner Development: August sales revenue of 1.225 billion yuan increased by 3.18% year-on-year

Sunner Development (002299) announced on the evening of September 9 that it achieved sales revenue of 1.225 billion yuan in August, an increase of 3.18% over the same period last year and a decrease of 2.72% from the previous month. Since 2021, the company's poultry breeding and food sector output has increased significantly compared with the previous year.

Red Star Development: The company's battery-grade lithium carbonate and other products have lower gross profit margins and smaller profit contributions

Red Star Development (600367) released a stock price change announcement on the evening of September 9, saying that in the first half of the year, the gross profit of the company's electrolytic manganese dioxide products was -5.3458 million yuan, accounting for -3.27% of the company's overall gross profit; the gross profit of high-purity manganese sulfate products was 429,700 yuan, accounting for 0.26% of the company's overall gross profit; the gross profit of battery-grade lithium carbonate was 7.2651 million yuan, accounting for 4.44% of the company's overall gross profit. The gross profit margin of the above products is low, and the contribution to the company's profit is relatively small.

Weifu Hi-Tech: Signed a strategic cooperation agreement on carbon neutrality demonstration projects with Wuxi High-tech Zone, etc

Weifu Hi-Tech (000581) announced on the evening of September 9 that the company signed the "Strategic Cooperation Framework Agreement on Carbon Neutrality Demonstration Projects" with the Management Committee of Wuxi High-tech Zone and Bosch China on the 8th, and the parties to the agreement will carry out multi-dimensional and in-depth cooperation around the goal of "carbon peaking and carbon neutrality". Chen Yudong, a director of the company, serves as the chairman of Bosch China, and Bosch Group, the actual controller of Bosch China, holds 14.16% of the company's shares.

Ice wheel environment: The two subsidiaries won the title of national specialized new "Little Giant" enterprise

Ice Wheel Environment (000811) announced on the evening of September 9 that the company's holding subsidiaries Beijing Huayuan Taimeng Energy Saving Equipment Co., Ltd. and Shandong Shenzhou Refrigeration Equipment Co., Ltd. were awarded the title of "Specialized Special New 'Little Giant Enterprise'" at the national level, and the title was valid for 3 years.

Fu'an Pharmaceutical: Clindamycin phosphate injection obtained the drug registration certificate

Fu'an Pharmaceutical (300194) announced on the evening of September 9 that its wholly-owned subsidiary, Guangan Kate, recently received a drug registration certificate for clindamycin phosphate injection issued by the State Food and Drug Administration. Clindamycin phosphate injection is mainly suitable for various infectious diseases caused by gram-positive bacteria and anaerobic bacteria, including tonsillitis, sinusitis, skin and soft tissue infections, urinary tract infections, etc.

Shimao shares: the first 8 months of sales signed about 23 billion yuan, an increase of 98% year-on-year

Shimao Co., Ltd. (600823) announced on the evening of September 9 that the company had no new real estate reserve projects in August. From January to August, the company's sales contract area was about 1.11 million square meters, an increase of 98% year-on-year; the sales contract amount was about 23 billion yuan, an increase of 98% year-on-year.

Sugon: Vehicle sales in the first eight months of 4874 units increased by 19.2% year-on-year

Shuguang (600303) disclosed the production and sales express report on the evening of September 9, and achieved vehicle sales of 161 vehicles in August, down 75.08% year-on-year. From January to August 2021, the cumulative sales volume of vehicles was 4874 units, an increase of 19.2% year-on-year.

Shuangcheng Pharmaceutical: Etiblotide injection ANDA was approved by the US FDA

Shuangcheng Pharmaceutical (002693) announced on the evening of September 9 that the simplified new drug application ("ANDA") submitted by the company for etiblotide injection (specification 20mg/10mL) has been approved by the US Food and Drug Administration ("FDA") for marketing authorization. Indications for etibalotide injection are anticoagulants and are used in patients with acute coronary syndrome.

ST Zhongchang: There is a risk of losing or out of control of the company's official seal

ST Zhongchang (600242) announced on the evening of September 9 that Lingyun has been elected as the chairman of the company, and the company's legal representative has been changed from Li Qunnan to Lingyun, and recently completed the industrial and commercial change. According to the company's regulations, Li Qunnan should transfer the company seal and license data inventory to the current chairman Lingyun, who will re-determine the custody department and personnel of the seal and license data in accordance with the regulations. Up to now, the company's official seal has not been handed over, and there is a risk that the above seal will be lost or out of control.

Sino Bio: Diabetes management system software obtained medical device registration certificate

Sino Bio (300298) announced on the evening of September 9 that the company's diabetes management system software was awarded the medical device registration certificate issued by the Hunan Provincial Food and Drug Administration. The acquisition of the medical device registration certificate has further improved the company's chronic disease management capabilities and enhanced the overall competitiveness of the company's products.

Xin Fengming: Gongqingcheng Shengbang intends to reduce its shareholding in the company by no more than 2%.

Xinfengming (603225) announced on the evening of September 9 that Gongqingcheng Shengbang Kaimi Investment Partnership (hereinafter referred to as "Gongqingcheng Shengbang"), a 7.71% shareholder, plans to reduce its holding of no more than 30.5913 million shares of the company in a centralized auction transaction within 6 months after 15 trading days, that is, no more than 2% of the total share capital of the company.

Poly Real Estate: The amount of contracts signed in the first 8 months was 374.214 billion yuan, an increase of 18.03% year-on-year

Poly Real Estate (600048) announced on the evening of September 9 that in August, the company achieved a signed area of 3.1208 million square meters, an increase of 10.6% year-on-year; the signed amount was 46.873 billion yuan, an increase of 6.76% year-on-year. From January to August, the company achieved a signed area of 22.9618 million square meters, an increase of 9.52% year-on-year; the signed amount was 374.214 billion yuan, an increase of 18.03% year-on-year.

Microchip Bio: Theoronic for the treatment of small cell lung cancer was certified as an orphan drug

Microchip Bio (688321) announced on the evening of September 9 that the company recently received an orphan drug qualification from the US Food and Drug Administration ("FDA"). The product name is Theoroni, and the indication is for the treatment of small cell lung cancer.

Dongfang Shenghong: The subsidiary's refining and chemical integration project was approved to use imported crude oil

Oriental Shenghong (000301) announced on the evening of September 9 that it received a reply from the General Office of the National Development and Reform Commission, the construction content of the refining and chemical integration project of the company's second-level subsidiary Shenghong Refining (Lianyungang) Co., Ltd. is 16 million tons / year refining and chemical integration project, in order to ensure the smooth production and operation of the project, in principle agreed that the project owner will use 16 million tons of imported crude oil / year, of which 2 million tons of imported crude oil will be used in 2021 and 15.89 million tons of imported crude oil will be used in 2022. From 2023, 16 million tons of imported crude oil will be used.

Shandong Glass Fiber: Oriental Boss intends to reduce the company's shares by no more than 1%.

Shandong Glass Fiber (605006) announced on the evening of September 9 that Orient Boss Venture Capital Co., Ltd. (hereinafter referred to as "Orient Boss"), a shareholder holding 16% of the shares, plans to reduce its holding of no more than 5 million shares (accounting for 1% of the company's total share capital) through a centralized auction transaction within 3 months after 15 trading days.

Hengrui Pharmaceutical: Non-busti tablets obtained a drug registration certificate

Hengrui Pharmaceutical (600276) announced on the evening of September 9 that recently, the company received the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration on non-busta tablets. Febuxta is indicated for long-term treatment of hyperuricemia in patients with gout.

Baosheng shares: won the bid for about 155 million yuan of wire and cable procurement projects

Baosheng Co., Ltd. (600973) announced on the evening of September 9 that the company won the bid for the 2021 wire and cable procurement project of Junfa Group, with a procurement amount of about 155 million yuan (including tax).

Anhui Construction Engineering: The subsidiary won a total bid of 1.71 billion yuan for the project

Anhui Construction Engineering (600502) announced on the evening of September 9 that its subsidiary, Anhui Highway and Bridge Engineering Co., Ltd., won the bid for the first section of the Jinzhai Road (Ring Expressway - Fangxing Avenue) rapid transformation project with a winning bid price of 1.204 billion yuan; its subsidiary, Anhui Sanjian Engineering Co., Ltd., won the bid for the construction project of Weilou Shantytown B and surrounding shantytowns in Xiaoxian County, with a winning bid of 507 million yuan.

Riying Electronics: 16.88 million yuan of land in Changzhou for the construction of intelligent auto parts projects

Riying Electronics (603286) announced on the evening of September 9 that the company recently bid for land use rights in Changzhou City, Jiangsu Province, with a land area of 37,497 square meters for 16.88 million yuan. The plot will be used to build the company's intelligent auto parts project.

Wasion Information: Received a total of 27.81 million yuan in government subsidies

Wasion Information (688100) announced on the evening of September 9 that the company and its holding subsidiaries have received a total of 27.8114 million yuan in government subsidies from February 27 to September 8, all of which are government subsidies related to revenue.

Healthcare: Multiple applications for drug registration were terminated

Weixinkang (603676) announced on the evening of September 9 that baiyi pharmaceutical, a wholly-owned subsidiary, submitted to the State Food and Drug Administration the withdrawal of ornithine aspartate injection, sucrose iron injection, invert sugar electrolyte injection, invert sugar injection and invert sugar injection drug registration application in accordance with the latest policy of the State Food and Drug Administration on drug review and approval, and combined with the actual situation of the company, and recently received the "Notice of Termination of Drug Registration Application" issued by the State Food and Drug Administration.

This article originated from the Financial Circle Network